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Functional Recapitulation of Smooth Muscle Cells Via
Induced Pluripotent Stem Cells From Human Aortic
Smooth Muscle Cells
Tae-Hee Lee,* Sun-Hwa Song, Koung Li Kim, Ji-Yeun Yi, Ga-Hee Shin, Ji Yeon Kim, Jihoon Kim,
Yong-Mahn Han, Sang Hun Lee, Suk-Ho Lee, Sung Han Shim, Wonhee Suh*
Rationale: Generation of induced pluripotent stem (iPS) cells has been intensively studied by a variety of
reprogramming methods, but the molecular and functional properties of the cells differentiated from iPS cells
have not been well characterized.
Objective: To address this issue, we generated iPS cells from human aortic vascular smooth muscle cells (HASMCs)
using lentiviral transduction of defined transcription factors and differentiated these iPS cells back into smooth
muscle cells (SMCs).
Methods and Results: Established iPS cells were shown to possess properties equivalent to human embryonic stem
cells, in terms of the cell surface markers, global mRNA and microRNA expression patterns, epigenetic status of
OCT4, REX1, and NANOG promoters, and in vitro/in vivo pluripotency. The cells were differentiated into SMCs
to enable a direct, comparative analysis with HASMCs, from which the iPS cells originated. We observed that
iPS cell–derived SMCs were very similar to parental HASMCs in gene expression patterns, epigenetic
modifications of pluripotency-related genes, and in vitro functional properties. However, the iPS cells still
expressed a significant amount of lentiviral transgenes (OCT4 and LIN28) because of partial gene silencing.
Conclusions: Our study reports, for the first time, the generation of iPS cells from HASMCs and their
differentiation into SMCs. Moreover, a parallel comparative analysis of human iPS cell–derived SMCs and
parental HASMCs revealed that iPS-derived cells possessed representative molecular and in vitro functional
characteristics of parental HASMCs, suggesting that iPS cells hold great promise as an autologous cell source for
patient-specific cell therapy. (Circ Res. 2010;106:120-128.)
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The therapeutic potential of embryonic stem (ES) cells isbased on the ability of ES cells to recover or replace
damaged tissues through self renewal and differentiation.1 As
a practical candidate for regenerative medicine, ES cells
should be harmonized with the immune system of the patient.
In the past, however, it was very difficult to make patient-
specific ES cells for several reasons. For example, somatic
cell nuclear transfer experiments with human oocytes have
been extremely inefficient and present ethical problems, and
methods to induce cell fusion between ES cells and somatic
cells present difficulties in removing ES cell chromosomes
from fused tetraploid pluripotent stem cells.2–4 However,
Yamanaka and colleagues recently developed a relatively
simple and highly innovative method for the generation of ES
cell–like pluripotent cells, so-called induced pluripotent stem
(iPS) cells, from human and mouse fibroblasts.5,6 Fibroblasts
were reprogrammed into an embryonic-like state by retroviral
transduction with 4 transcription factors (OCT4, SOX2,
KLF4, and c-MYC), and these reprogrammed cells were
shown to be remarkably similar to ES cells, in terms of
morphology, gene expression, and differentiation potential in
vitro and in vivo.5,6 Simultaneously, Thomson and colleagues
reported the generation of iPS cells from human fibroblasts
by using a different gene combination (OCT4, SOX2,
NANOG, and LIN28) than that used by Yamanaka and
colleagues.7 In addition, several other investigators have
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reported the generation of human iPS cells from adult somatic
cells, mostly fibroblasts, indicating that iPS cell technology is
likely to be highly reproducible.8–10 Because it successfully
overcomes serious limitations imposed by previous technol-
ogies, such as somatic cell nuclear transfer and cell fusion,
iPS cell technology is expected to advance the development
of patient-specific cell therapy by providing abundant, pluri-
potent patient-specific stem cells. In addition, iPS cell tech-
nology can be used to construct cell based-model systems for
studying human inherited genetic disorders, an effort which
has been limited because of the difficulty of isolating or
maintaining symptomatic cells from patients.
Successful application of iPS cell technologies depends on
the assumption that cells differentiated from patient-derived
iPS cells have the same, or substantially similar, characteris-
tics to those of the somatic cells of the patient. Therefore, it
is necessary to perform a comparative analysis of the molec-
ular and biological properties of cells differentiated from iPS
cells and those of the same lineaged somatic cells from which
the iPS cells were originated. To address this issue, we
generated iPS cells from human aortic vascular smooth
muscle cells (HASMCs) and differentiated these iPS cells
back into smooth muscle cells (SMCs). We then character-
ized and compared the gene expression and cellular function-
ality of iPS cell–derived SMCs with the parental HASMCs
from which the iPS cells were derived.
Methods
Reagents
Human recombinant basic fibroblast growth factor was obtained
from R&D Systems (Minneapolis, Minn). Primary antibodies used in
the study were SSEA-4, NANOG, OCT4, AP (R&D Systems),
-smooth muscle actin (-SMA) (Dako Inc, Carpinteria, Calif),
vimentin (Abcam, Cambridge, MA), -fetoprotein (R&D Systems),
and -III tubulin (Chemicon International Inc, Temecula, Calif).
Growth factor–reduced Matrigel was purchased from BD Bio-
sciences Inc (Palo Alto, Calif).
Cell Culture
Human ES cells (H9; Wicell Research Institute, Madison, Wis) and
iPS cells were cultured on 60-mm dishes containing mitomycin
C–treated mouse embryonic fibroblast (MEF) feeder cells in stan-
dard human ES cell medium (ReproCell Inc, Tokyo, Japan). For
passaging, human iPS cells were incubated with ES dissociation
solution (ReproCell Inc) at 37°C. When colonies were detached from
the dishes, dissociation solution was aspirated. Cell clusters were
washed with ES cell medium and collected in 1.5 mL tubes. After the
spontaneous precipitation of pellets for 5 minutes, medium was
washed out and cells were resuspended with fresh medium. Cells
were then transferred to a new dish with MEF or STO feeder cells
and maintained in ES cell medium containing 5 ng/mL basic
fibroblast growth factor. STO cells were maintained in DMEM
containing 10% FBS, 1% penicillin, and streptomycin. HASMCs
were purchased from ScienCell Research Laboratories (Carlsbad,
Calif) and maintained in SMC-specific medium, SMCM (ScienCell
Research Laboratories). HUVECs were purchased from Cambrex
Bio Science Inc (Walkersville, Md) and cultured with endothelial
growth medium (EGM)-2.
Lentiviral Transduction and iPS Cell Generation
Human full length cDNAs for OCT4, SOX2, NANOG, LIN28, and
KLF4 were subcloned into a modified pLenti6/R4R2/V5-DEST
lentiviral vector (Invitrogen Inc, Carlsbad, Calif) with human elon-
gation factor-1 promoter. Plasmids were transiently transfected
with other packaging plasmids into 293FT cells, according to the
protocol of the manufacturer (Invitrogen Inc). After the appropriate
viral preparation, lentiviral supernatant was added to the HASMC
dish at a 1:1 (vol/vol) ratio with SMCM in the presence of polybrene
(8 g/mL) for 12 hours. After 12 hours, cells were second-infected
with the lentiviral supernatant for an additional 12-hour period. Cells
were then maintained in fresh SMCM containing blastcidin (Invitro-
gen Inc) for subsequent 4 days. After trypsinization, 5104 trans-
duced cells were transferred to 100-mm dishes containing mitomycin
C–treated MEF. The next day, the medium was replaced with human
ES medium and changed every other day thereafter. After 3 weeks,
colonies with ES cell morphology were manually picked and
transferred to new dishes containing mitomycin C–treated MEF for
the further expansion.
Immunocytochemistry
Immunocytochemistry was performed according to the previously
described method.11 Briefly, cells were grown on cover glass and
fixed in 4% paraformaldehyde. They were permeabilized with PBST
(0.1% Triton X-100 in PBS), incubated with blocking solution (Dako
Inc), and subsequently incubated overnight with primary antibodies
in blocking solution. Cells were then washed and incubated with
Alexa 488– or Alexa 594–conjugated secondary antibodies (Invitro-
gen Inc) diluted at a ratio of 1:250 (vol/vol) in blocking solution for
1 hour at room temperature. Visualization was accomplished using a
Zeiss LSM 500 confocal microscope.
Teratoma Formation
Approximately 1106 iPS cells were suspended in a DMEM/
Matrigel solution (BD Biosciences Inc) at a ratio of 1:1 (vol/vol), and
the cell/Matrigel suspension was subcutaneously injected into the
dorso-lateral area of NOD/SCID mice (Charles River Laboratories,
Yokohama, Japan). Six weeks after injection, mice were anesthetized
by intraperitoneal injection of ketamine-xylazine (50 mg/kg and 5
mg/kg, respectively). Xenografted masses were harvested, fixed,
embedded in paraffin, and sectioned. Tissue sections were stained
with hematoxylin/eosin, oil red O, or antibodies against nestin and
cytokeratin 17 (R&D Systems). The experiments were reviewed and
approved by the Institutional Animal Care and Use Committee of
Pochon CHA University. All procedures were performed in accor-
dance with the Guidelines for the Care and Use of Laboratory
Animals (NIH publication no. 85-23, revised 1996).
SMC Differentiation and Isolation
To differentiate iPS or H9 cells into SMCs, embryoid bodies (EBs)
were transferred to gelatin-coated plate and maintained in SMCM
medium for 10 days. Colonies with SMC-like cell morphology were
manually picked and examined for the expression of SMC-specific
Non-standard Abbreviations and Acronyms
EB embryoid body
ES embryonic stem
iPS induced pluripotent stem
MEF mouse embryonic fibroblast
HASMC human aortic vascular smooth muscle cell
miRNA microRNA
SES smooth muscle cell–derived ES-like
SMA smooth muscle actin
SMC smooth muscle cell
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marker genes. Positive cells were transferred to new culture dishes
for further expansion, and were checked for their expression of
SMC-specific marker genes. During the course of the experiment,
the cells were used until passages 3 to 10 and were checked routinely
for the -SMA expression.
Bisulfite Genomic Sequencing
Genomic DNA was subjected to sodium bisulfite treatment using the
EZ DNA Methylation-Gold Kit according to the protocol of the
manufacturer (Zymo Research, Orange, Calif). Aliquots of bisulfite-
treated DNA (25 to 50 ng) were amplified by PCR.
The resulting amplified products were purified by using Nucle-
oSpin Extract Kit (MACHEREY-NAGEL, Germany), and sub-
cloned into pGEM-T EASY vector (Promega, Madison, Wis). For
each cell type, 10 clones were sequenced using M13R primers.
Sequencing results were further analyzed by using a web-based
program (Blast-2) or software (BiQ Analyzer). A bisulfite conver-
sion of at least 95% was accepted. Primer sequences for OCT4,
REX1, and NANOG promoter are listed in Table V in the Online
Data Supplement, available at http://circres.ahajournals.org.
Cytosolic Ca2 Measurement
Cytosolic [Ca2] in SMCs was measured according to the previously
described method.12 Briefly, cells were incubated with normal
Tyrode solution (NaCl 148 mmol/L, KCl 5 mmol/L, CaCl2
2 mmol/L, MgCl2 1 mmol/L, glucose 10 mmol/L, Hepes 10 mmol/L,
pH 7.4) containing 2 mol/L Fura-2 acetoxymethyl ester/0.1%
pluronic F-127 for 15 minutes at room temperature. Ca2 transients
were evoked by the treatment of 50 mmol/L of KCl or 5 mol/L
carbachol. The fluorescence imaging of SMCs was performed
using a 40 water immersion objective (LUMPlanFl, Olympus)
and charge-coupled device camera (SensiCam, PCO, Kelheim,
Germany). Images were taken with double wavelength excitation at
340 and 380 nm. A ratio of fluorescence intensity at 340 and 380 nm
(F340/F380) was regarded as a parameter representing cytosolic [Ca
2].
Results
Generation of iPS Cells
For the generation of iPS cells from somatic HASMCs, we
first examined expression of reprogramming transcription
factors in HASMCs by using quantitative RT-PCR. As
compared with expression levels in H9, human ES cells, the
expression of OCT4, SOX2, NANOG, and LIN28 in
HASMCs were markedly low, whereas the expression of
KLF4 was moderately low (Figure 1A). Furthermore, the
expression of c-MYC was very low in both cell lines (Figure
Figure 1. Generation and characterization
of iPS cells from HASMCs. A, Quantita-
tive RT-PCR analyses of the endogenous
expression of OCT4, NANOG, SOX2,
LIN28, KLF4, and c-MYC in human ES
cells (H9, black bar) and HASMCs (gray
bar) (n3; meansSEM). B, Expression
profile of human ES cell marker genes,
endogenous genes, and lentiviral trans-
genes in iPS cell clones. NES indicates
non–ES-like cells; endo, endogenous
genes; exo, lentiviral transgenes; total,
endoexo. RT-PCR analysis specific for
lentiviral DNA showed the presence or
absence of transgene expression in iPS
cells. GAPDH was used as a loading con-
trol in RT-PCR. C, Representative immu-
nofluorescence analysis of iPS cells. Clear
expression of ES cell–specific surface
antigens such as TRA-1 to 60, TRA-1 to
-81, NANOG, and OCT4 was observed.
Nuclei were stained with DAPI. Scale
bar100 m. D, Karyotyping analysis of
SES8 cells. E and F, Scatter plots com-
paring the (E) global mRNA and (F)
miRNA expression patterns between iPS
cells (SES8) and H9 cells and between
SES8 cells and parental HASMCs. Red
lines indicate 2-fold changes in mRNA or
miRNA expression levels between the
paired cells. Positions of selected mRNA
and miRNA were indicated as arrows in
scatter plots.
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1A). From these results, we speculated that c-MYC, a potent
oncogene,14,15 was not absolutely necessary for generating
iPS cells from HASMCs. In this study, the 5 transcription
factors that showed relatively low expression levels in the
HASMCs were used to reprogram HASMCs into iPS cells.
Therefore, lentiviruses containing human OCT4, SOX2,
KLF4, NANOG, and LIN28 were introduced into HASMCs.
After culturing transduced HASMCs onto MEF feeder cells
for 3 weeks, 10 human ES cell–like colonies and 2 fibroblast-
like cell clusters (non-ES (NES) cells; negative controls)
were manually picked, cultured, and expanded. The effi-
ciency of the generation of iPS cells from HASMCs was
0.002% and comparable to the previous reports.6,7
Of the 6 iPS cells initially established, 2 iPS cell lines
(SES3 and SES8; SMC-derived ES-like cells are designated
as SES cells in this study) have been maintained in continu-
ous culture to date, a period which represents more than 30
passages. As shown in Online Figure I, the morphology of the
SES8 cells was very similar to that of H9 cells.
Characterization of iPS Cells
We first characterized the expression of human ES cell
marker genes and lentiviral reprogramming transgenes in the
established iPS cells. RT-PCR analysis showed that the 6 SES
cell lines exhibited strong expression of stemness marker
genes (UTF1, hTERT, LEFTB, TDGF1, and GDF3) and
reactivation of pluripotency-related endogenous genes
(OCT4, SOX2, and NANOG), whereas the parental
HASMCs and NES cells did not (Figure 1B). These results
were further confirmed by immunofluorescence analysis data
which showed SES cells stained strongly positive for human
ES cell–specific markers such as TRA-1 to -60, TRA-1 to
-81, NANOG, and OCT4 (Figure 1C). When the expression
of lentiviral transgenes was examined using specific primers,
4 SES cell lines (SES3, -5, -9, and -10) showed expression of
all 5 transgenes, whereas 2 SES cell lines (SES2 and -8) were
found to express only 4 transgenes (Figure 1B). In particular,
the SES8 cells contained exogenous OCT4, SOX2, NANOG,
and LIN28 genes, which constitutes the same combination of
genes used previously by Thompson and his colleagues.7
Genomic PCR analysis confirmed that the lack of NANOG or
KLF4 gene expression in the SES2 and SES8 cells was
attributable to the absence of the lentiviral transgene integra-
tion but not attributable to gene silencing (data not shown).
Karyotyping and DNA fingerprinting analyses demonstrated
that SES8 cells comprised normal chromosome (Figure 1D)
and were derived from HASMCs, not from the contamination
of female H9 cells which were the only human ES cells
available in our laboratory (Online Table I).
Global Gene Expression Profile of Human
iPS Cells
cDNA microarrays were used to compare the global gene
expression patterns between SES8 cells and H9 cells, and
between the SES8 cells and HASMCs. Scatter plots of these
data showed an intensive correlation of SES8 cells with H9
cells, as compared with HASMCs from which the SES8 cells
were derived (Figure 1E). Notably, SES8 cells exhibited
strong induction of developmental pluripotency-associated 4
(DPPA4), DNA methyltransferase 3B (DNMT3B), sal-like 4
(SALL4), and reduced expression 1 (REX1) genes similar to
levels observed in H9 cells, and substantial loss of SMC-
specific genes including collagen type VI 3 (COL6A3),
COL1A2, SMA 2 (ACTA2), and fibulin 5 (FBLN5) (Online
Table II). In addition, we investigated whether micro
(mi)RNA expression was changed during reprogramming
processes. micro (mi)RNA patterns showed a higher degree
of similarity between SES8 cells and H9 cells, than between
SES8 cells and HASMCs (Figure 1F). In particular, ES
cell–specific miR302-367 clusters, recently reported to be
regulated by OCT4, NANOG and SOX2,16,17 were highly
expressed in both SES8 cells and H9 cells, in contrast to a 50-
to 200-fold lower expression level observed in HASMCs.
These data demonstrated that SES8 cells reprogrammed from
HASMCs became highly similar to human ES cells in terms
of miRNA, as well as mRNA expression patterns.
Figure 2. Pluripotency of HASMC-derived iPS cells. A, In vitro
EB-mediated differentiation of SES8 cells into 3 germ layers.
EBs were cultured in differentiation medium on gelatin-coated
plate and stained with -fetoprotein (endoderm), -SMA (meso-
derm), vimentin (mesoderm), or 3-tubullin (ectoderm). Nuclei
were stained with DAPI. Scale bar100 m. B, Changes in the
expression levels of endogenous pluripotency-related genes and
various differentiation markers were assessed in undifferentiated
(U) and in vitro-differentiated (D) SES8 and H9 cells using
RT-PCR. C, Teratoma derived from SES8 cells containing all 3
germ layers. Teratoma were harvested 6 weeks after subcutane-
ous injection of SES8 cells into NOD/SCID immunodeficient
mice, and their sections were stained with hematoxylin/eosin, oil
red O (adipocyte, mesoderm), and antibodies against nestin
(neural rosette, ectoderm) and cytokeratin 17 (gut-like epithe-
lium, endoderm). Scale bar200 m.
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In Vitro Differentiation and Teratoma Formation
of the iPS Cells
An EB culture system was used to determine whether human
iPS cells exhibited an ability to differentiate into 3 germ
layers in vitro. Cells differentiated from SES8 cells stained
positively for endoderm (-fetoprotein), mesoderm (-SMA,
vimentin), and ectoderm (III-tubulin) markers (Figure 2A).
In accordance with these immunofluorescence data, RT-PCR
analysis revealed that EB-mediated differentiation signifi-
cantly upregulated forkhead box A2 (FOXA2, endoderm),
BRACHYURY (mesoderm), paired box 6 (PAX6, ectoderm),
and caudal-related protein (CDX2, trophectoderm) but mark-
edly reduced the endogenous expression of OCT4, SOX2,
and NANOG in both SES8 cells and H9 cells (Figure 2B).
Furthermore, the pluripotency of SES8 cells in vivo was
confirmed by subcutaneous transplantation into the lateral
dorsal region of immunodeficient mice. Six weeks after cell
injection, teratoma that contained derivatives of all 3 germ
layers, including gut-like epithelium (cytokeratin 17,
endoderm), adipose tissues (oil-red O, mesoderm), and neural
tissues (nestin, ectoderm), were readily observed (Figure 2C).
Taken together, these data demonstrated that SES8 cells had
the capacity to differentiate to 3 germ layers both in vitro and
in vivo.
Differentiation of iPS Cells Into SMCs
To differentiate SES8 cells into SMCs, EBs were seeded on
gelatin-coated plates and maintained in SMC differentiation
medium for 10 days. Colonies having SMC-like morphology
were manually picked and transferred onto new culture dishes
for further expansion and characterization. From these exper-
iments, 2 SES8-derived SMC-like cell lines (SES8-SMC1
and SES8-SMC3) were established, in which all cells
strongly expressed SMC-specific marker, -SMA (Figure
3A), and they were confirmed to be derived from SES8 cells
by DNA fingerprinting analysis (Online Table I).
With the same differentiation method, H9 cells were
differentiated into -SMA–positive cells (H9-SMCs), which
were used as a positive control for the characterization of
SES8-derived SMCs (Figure 3A). RT-PCR analysis revealed
that differentiated SMCs (SES8-SMC1, SES8-SMC3, and
H9-SMCs) barely expressed endogenous pluripotency-related
transcriptional factors (OCT4, NANOG, and SOX2) or stem-
ness marker genes (TDGF1, LEFGB, GDF3, and UTF1)
(Figure 3B). To examine quantitative expression of known
SMC-specific genes including -SMA, smooth myosin heavy
chain, calponin, myocardin, and caldesmon in SMCs derived
from SES8 and H9 cells, we performed real-time RT-PCR.
We found that SES8 and H9 cells constitutively expressed
smooth myosin heavy chain, calponin, myocardin, and
caldesmon, as did SMCs, implying that these genes may be
not good indicators for differentiation of ES or iPS cells into
SMCs (data not shown). However, we found that - and
-SMA were barely expressed in SES8 and H9 cells, whereas
these genes were highly expressed in HASMCs, suggesting
Figure 3. Generation of SMCs from iPS cells.
A, -SMA expression in HASMCs, iPS cell–,
and H9 cell–derived SMCs (SES8-SMC1,
SES8-SMC3, H9-SMC). Scale bar100 m.
RT-PCR analyses showing the markedly
reduced expression of endogenous
pluripotency-related genes and human ES cell
marker genes (B) and the expression of SMC
marker genes (- and -SMA) (C) but not skel-
etal myocyte-specific (MyoD, myogenin), car-
diomyocyte-specific (CTNT, CTNI), or endothe-
lial cell–specific (CD31, Tie2) genes (D) in
SES8-SMCs and H9-SMCs. GAPDH was used
as a loading control.
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that - and -SMA may be suitable markers for SMCs
differentiated from human ES and iPS cells. When - and
-SMA expression was assessed with real time RT-PCR, they
were found to be strongly induced in both H9-SMCs and
SES8-SMCs (Figure 3C).
When the expression of skeletal myocyte–specific (Myo D
and Myogenin), cardiomyocyte-specific (CTNI and CTNT)
or endothelial cell–specific (CD31 and Tie2) genes were
examined using RT-PCR, these genes were expressed at very
low levels in SMCs, compared with H9 or SES8-derived EB
(Figure 3D).
Gene Expression Profile and Epigenetic
Modification of iPS Cell–Derived SMCs
The global gene expression profiles of SES8-SMCs,
HASMCs, and SES8 cells were compared by using cDNA
microarrays. Scatter plot analyses showed that the gene
expression patterns of 2 SES8-derived SMCs and H9-derived
SMCs were more closely correlated with expression patterns
of HASMCs than with those of SES8 and H9 cells (Figure
4A). Online Table III provides a detailed comparison of
SES8-, H9-derived SMCs, and HASMCs with regard to
transcript levels of key genes determining SMC differentia-
tion (MRTF-A/B [myocardin-related transcription factor],
myocardin, serum response factor) and function (contractile
proteins; SM22-, -SMA, and ion channels; Cav1.2, Slo).18
These data highlighted that SMCs differentiated from iPS or
H9 cells displayed mature SMC characteristics at the tran-
scription level. However, closer examination of differentially
expressed genes between SES8-SMCs and HASMCs showed
that SES8-SMCs exhibited relatively high, though much
lower than SES8 cells, expression of ES cell–specific genes,
such as OCT4, LIN28, SALL4, and DPPA4, but not REX1
and AP, whereas H9-SMCs barely expressed these genes
(Online Table IV). Quantitative RT-PCR results revealed that
the expression of endogenous OCT4, SOX2, and NANOG
genes were dramatically silenced during the differentiation of
SES cells into SMCs, as observed in the differentiation of H9
cells into SMCs, whereas some lentiviral transgenes (OCT4
and LIN28) remained expressed in SES8-SMCs (Figure 4B).
This result showed that residual expression of OCT4 and
LIN28 in SES8-SMCs was derived from the lentiviral trans-
genes incorporated in SES8 cells but not from endogenous
counterparts. Bisulfite genomic sequencing analyses revealed
that promoter or enhancer regions of ES-specific marker
genes such as OCT4, REX1 and NANOG were substantially
demethylated in SES8 cells, indicating the epigenetic repro-
gramming into pluripotent ES-like state (Figure 4C). More-
over, the results showed that SES8-SMCs exhibited promi-
nent promoter methylation patterns of OCT4, REX1, and
NANOG similar to those of HASMCs, implying that the in
Figure 4. Gene expression profiles of iPS cell–derived SMCs. A,
Scatter plots comparing the global gene expression patterns
between SES8- or H9-SMCs and HASMCs and between SES8- or
H9-SMCs and their undifferentiated counterparts (SES8, H9). Red
lines indicate 2-fold changes in gene expression levels between the
paired cells. B, Quantitative RT-PCR analysis of the expression lev-
els of endogenous and exogenous reprogramming factors (n3;
meansSEM). C, DNA methylation patterns of OCT4, REX1, and
NANOG promoters in iPS cells, H9 cells, iPS cell–derived SMCs,
and HASMCs, as determined by bisulfite genomic sequencing.
Open and filled circles indicate unmethylated and methylated CpG
dinucleotides, respectively. Each horizontal line represents an indi-
vidual clone. Percentages indicate methylation levels, calculated as
the number of methylated CpG per total number of CpG
sequences.
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vitro differentiation of SES8 cells into SMCs epigenetically
knocked down the expression of endogenous pluripotency-
related genes.
Functional Characterization of SES8-SMCs
Next, we investigated whether iPS cell–derived SMCs have
functional properties similar to somatic SMCs. Here, the
calcium influx and subsequent contraction in response to
vasoconstrictors, one of requisite characteristics of SMCs,
was evaluated in SES8-SMCs and HASMCs. Fura-2 ace-
toxymethyl ester, a Ca2-sensitive dye, was used to monitor
the intracellular calcium influx on addition of KCl or carba-
chol. SES8-SMCs exhibited increased intracellular calcium
influx in response to vasoconstrictive carbachol and KCl-
induced membrane depolarization similar to that of parental
HASMCs (Figure 5A and 5B). Moreover, treatment with
carbachol or angiotensin II induced a significant contraction
of SES8-SMCs as observed in HASMCs (Figure 5C and 5D;
Online Movies). Karyotyping analysis showed that SES8-
SMC1 cells contained normal chromosomes (Figure 5E).
Taken together, these results demonstrated that in in vitro
conditions, the SMCs differentiated from SES8 human iPS
cells possessed SMC-specific functionalities comparable to
parental HASMCs.
Discussion
Since the recent discovery of iPS cell technology, many
researchers have reported that iPS cells can be derived from
mouse and human somatic cells by the viral transduction of
defined reprogramming transcription factors. In mouse, iPS
cells have been produced from a variety of lineage-committed
somatic cells, such as fibroblasts,6 hepatocytes,19 B lympho-
cytes,20 and neural stem cells.8 However, most human iPS
cells have been generated from fibroblasts or fibroblast-like
synoviocytes,6,7,9,10 with the exception of one recent report
about iPS cell generation from human keratinocytes.21 Our
present study showing iPS cell generation from human aortic
SMCs implies that human iPS cells, like murine iPS cells, can
be generated from diverse somatic cell origins. Here, several
iPS cell clones were generated by introducing 4 or 5 known
reprogramming factors (OCT4, SOX2, NANOG, LIN28,
and/or KLF4) into HASMCs. Among them, the SES8 cell
clone with the same 4 lentiviral transgenes (OCT4, SOX2,
NANOG, and LIN28) as those used by the Thomson labora-
tory was intensively analyzed and determined to have ES
cell–specific properties.
It is thought that iPS cell technology may enable the
generation of patient-specific, immunocompatible, pluripo-
tent stem cells, which could potentially differentiate into any
cell type for the treatment of incurable human diseases. In
Figure 5. Functional characterization of
iPS cell–derived SMCs. A, Representative
graphs showing relative change in intra-
cellular [Ca2] in response to membrane
depolarization (50 mmol/L KCl, black line)
and vasoconstrictor (5 mol/L carbachol,
gray line) in SES8-SMCs (SES8-SMC1 ;
SES8-SMC3 [middle]) and HASMCs (bot-
tom). Concentration of intracellular cal-
cium, [Ca2]i, was measured with calcium
indicator Fura-2 acetoxymethyl ester and
expressed as a ratio of fluorescence
intensity at 340 and 380 nm (F340/F380).
The arrowheads and arrows show the
time point for application of KCl and car-
bachol, respectively. B, Bar graphs show-
ing the net changes in [Ca2]i on the
treatment of KCl (white) or carbachol
(black). (Changes of [Ca2]ipeak
[Ca2]iresting [Ca
2]i; n13;
meansSEM.) C, Representative images
showing the contraction of HASMCs,
SES8-SMC1, and SES8-SMC3 in response
to carbachol. Bright-field images were
taken before and 30 minutes after adminis-
tration of carbachol (5 mol/L). D, Collagen
gel contraction assay of SMCs in response
to vasoconstrictors. Collagen gels embed-
ded with SES8-SMC1, SES8-SMC3, and
HASMCs were incubated in basal -MEM
media without (white) or with carbachol
(gray) or angiotensin II (black). The extent of
SMC collagen gel contraction was esti-
mated by dividing the gel size at 20 min-
utes by the initial gel size (n3;
meansSEM). *P0.05 vs each -MEM
media control. E, Karyotyping analysis of
iPS cell–derived SMCs.
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fact, several recent studies have shown that human iPS cells
can be successfully differentiated into a variety of somatic
cells including pancreatic  cells,22 cardiomyocytes,23 and
neuronal cells.24 Although these reports have described the
great therapeutic potentials of cells differentiated from iPS
cells, clinical applications will likely require more extensive
data regarding how closely these cells represent the patient’s
somatic cells. With this rationale, we differentiated SES8 iPS
cells back into SMCs and compared the genetic, epigenetic,
and functional properties of SES8-derived SMCs with those
of the parental HASMCs. SMCs differentiated from iPS cells
were isolated homogeneously and maintained in in vitro
long-term culture, without development of chromosomal
abnormality. We found that 2 SMC clones (SES8-SMCs)
differentiated from SES8 cells possessed not only global gene
expression patterns similar to that of the parental HASMCs
but also possessed SMC-specific functionalities such as the
calcium influx and subsequent contraction in response to
vasoconstrictors. However, SES8-SMCs expressed substan-
tial levels of OCT4, LIN28, and several ES-specific genes
that were, however, barely expressed in H9-SMCs. This
residual expression of OCT4 and LIN28 resulted from the
incomplete silencing of the corresponding lentiviral trans-
genes but not endogenous genes. In H9-SMCs, endogenous
OCT4 and LIN28 were completely repressed under the same
differentiation conditions, indicating that the differentiation
method used in this study was sufficient to induce the
complete differentiation of human ES cells into SMCs. When
expression of the OCT4 transgene in SES8-SMCs was
reduced by OCT4 small interfering RNA, these cells were not
only elongated and spreading similar to HASMCs or H9-
derived SMCs but also upregulated the SMC specific genes
(-SMA and myocardin) and downregulated the stemness
genes (SALL4 and DPPA4) (see Online Figure II). These
results indicate that the complete silencing of lentiviral
transgenes in SES8 cells is necessary to induce complete
differentiation into SMCs. Thus, our present study demon-
strates that reprogramming of somatic cells without genome
integration of transgenes should be strongly recommended to
achieve complete differentiation of iPS cells.
Indeed, the Hochedlinger and Yamanaka groups have
reported the generation of murine iPS cells by using a
nonintegrating adenovirus delivery system or by using tran-
sient transfection with plasmids.25,26 Recently, Jaenisch and
colleagues have reported the generation of human iPS cells
without genome integration of transgenes by using a Cre-lox
system.27 These reports introduce the possibility of practical
application of iPS cell technology for regenerative medicine
and genetic disorder research.
The present study is the first, to our knowledge, to report
the generation of iPS cells from HASMCs and their differ-
entiation back into SMCs. Moreover, the parallel comparative
analysis of human iPS cell–derived SMCs and parental
HASMCs showed that iPS cell–derived SMCs exhibited
representative molecular and in vitro functional characteris-
tics of parental HASMCs, suggesting that iPS cells hold great
promise as an autologous cell source for patient-specific cell
therapy.
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